

## Literatur

1. Maiuri A. Measles virus particle 3D graphic. <https://phil.cdc.gov/Details.aspx?pid=21074>; CDC; 2016.
2. Hübschen JM, Gouandjika-Vasilache I, Dina J. Measles. Lancet (London, England). 2022;399(10325):678-90.
3. Orenstein W, Offit P, Edwards K, Plotkin S. Plotkin's Vaccines. Philadelphia, PA: Elsevier; 2024.
4. Bloch AB, Orenstein WA, Ewing WM, Spain WH, Mallison GF, Herrmann KL, et al. Measles outbreak in a pediatric practice: airborne transmission in an office setting. Pediatrics. 1985;75(4):676-83.
5. Remington PL, Hall WN, Davis IH, Herald AL, Gunn RA. Airborne transmission of measles in a physician's office. JAMA. 1985;253(11):1574-7.
6. Riley EC, Murphy G, Riley RL. Airborne spread of measles in a suburban elementary school. American journal of epidemiology. 1978;107(5):421-32.
7. Jong Jd. The survival of measles virus in air. Antonie van Leeuwenhoek. 2005;29:327-8.
8. Eichenwald H. Measles skin rash [Picture]. <https://phil.cdc.gov/Details.aspx?pid=3168>; : CDC; 1958.
9. Rota JS, Hickman CJ, Sowers SB, Rota PA, Mercader S, Bellini WJ. Two case studies of modified measles in vaccinated physicians exposed to primary measles cases: high risk of infection but low risk of transmission. J Infect Dis. 2011;204 Suppl 1:S559-63.
10. Zhang Z, Chen M, Ma R, Pan J, Suo L, Lu L. Outbreak of measles among persons with secondary vaccine failure, China, 2018. Human vaccines & immunotherapeutics. 2020;16(2):358-62.
11. Kurata T, Kanbayashi D, Egawa K, Kinoshita M, Yoshida H, Miyazono M, et al. A measles outbreak from an index case with immunologically confirmed secondary vaccine failure. Vaccine. 2020;38(6):1467-75.
12. Rosen JB, Rota JS, Hickman CJ, Sowers SB, Mercader S, Rota PA, et al. Outbreak of measles among persons with prior evidence of immunity, New York City, 2011. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014;58(9):1205-10.
13. Iwamoto M, Hickman CJ, Colley H, Arciuolo RJ, Mahle CE, Deocharan B, et al. Measles infection in persons with secondary vaccine failure, New York City, 2018-19. Vaccine. 2021;39(38):5346-50.
14. Fitzgerald TL, Durrheim DN, Merritt TD, Birch C, Tran T. Measles with a possible 23 day incubation period. Commun Dis Intell Q Rep. 2012;36(3):E277-80.
15. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291-300.
16. World Health Organization. Measles vaccines: WHO position paper, April 2017 - Recommendations. Vaccine. 2019;37(2):219-22.
17. Moss WJ, Griffin DE. What's going on with measles? J Virol. 2024;98(8):e0075824.
18. Buchanan R, Bonthius DJ. Measles virus and associated central nervous system sequelae. Seminars in pediatric neurology. 2012;19(3):107-14.
19. Hosoya M. Measles encephalitis: direct viral invasion or autoimmune-mediated inflammation? Internal medicine (Tokyo, Japan). 2006;45(14):841-2.
20. Pohl D, Alper G, Van Haren K, Kornberg AJ, Lucchinetti CF, Tenembaum S, et al. Acute disseminated encephalomyelitis: Updates on an inflammatory CNS syndrome. Neurology. 2016;87(9 Suppl 2):S38-45.
21. Ali D, Detroz A, Gorur Y, Bosque Lee L, Villalba NL, Cardos B. Measles-induced Acute Disseminated Encephalomyelitis in a Non-vaccinated Patient. European journal of case reports in internal medicine. 2020;7(6):001322.
22. McMickle R, Fryling L, Fleischman R. Acute Demyelinating Encephalomyelitis Following Measles Infection Due to Vaccine Failure: A Case Report. Clin Pract Cases Emerg Med. 2021;5(2):171-3.
23. Fisher DL, Defres S, Solomon T. Measles-induced encephalitis. QJM. 2015;108(3):177-82.
24. Garg RK, Mahadevan A, Malhotra HS, Rizvi I, Kumar N, Uniyal R. Subacute sclerosing panencephalitis. Reviews in medical virology. 2019;29(5):e2058.
25. Lebon P, Gelot A, Zhang SY, Casanova JL, Hauw JJ. Measles Sclerosing Subacute PanEncephalitis (SSPE), an intriguing and ever-present disease: Data, assumptions and new perspectives. Rev Neurol (Paris). 2021;177(9):1059-68.
26. Schönberger K, Ludwig MS, Wildner M, Weissbrich B. Epidemiology of subacute sclerosing panencephalitis (SSPE) in Germany from 2003 to 2009: a risk estimation. PloS one. 2013;8(7):e68909.
27. Wendorf KA, Winter K, Zipprich J, Schechter R, Hacker JK, Preas C, et al. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017;65(2):226-32.
28. Mathieu C, Bovier FT, Ferren M, Lieberman NAP, Predella C, Lalande A, et al. Molecular Features of the Measles Virus Viral Fusion Complex That Favor Infection and Spread in the Brain. mBio. 2021;12(3):e0079921.
29. Griffin DE. Measles immunity and immunosuppression. Current opinion in virology. 2021;46:9-14.
30. Mina MJ. Measles, immune suppression and vaccination: direct and indirect nonspecific vaccine benefits. J Infection. 2017;74:S10-S7.
31. Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science (New York, NY). 2019;366(6465):599-606.
32. Mina MJ, Metcalf CJ, de Swart RL, Osterhaus AD, Grenfell BT. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science (New York, NY). 2015;348(6235):694-9.
33. Laksono BM, de Vries RD, Duprex WP, de Swart RL. Measles pathogenesis, immune suppression and animal models. Current opinion in virology. 2020;41:31-7.
34. Laksono BM, de Vries RD, McQuaid S, Duprex WP, de Swart RL. Measles Virus Host Invasion and Pathogenesis. Viruses. 2016;8(8).
35. Laksono BM, de Vries RD, Verburgh RJ, Visser EG, de Jong A, Fraaij PLA, et al. Studies into the mechanism of measles-associated immune suppression during a measles outbreak in the Netherlands. Nat Commun. 2018;9(1):4944.
36. Petrova VN, Sawatsky B, Han AX, Laksono BM, Walz L, Parker E, et al. Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles. Science immunology. 2019;4(41).
37. Abbas M, Aloudat T, Bartolomei J, Carballo M, Durieux-Paillard S, Gabus L, et al. Migrant and refugee populations: a public health and policy perspective on a continuing global crisis. Antimicrobial resistance and infection control. 2018;7:113.
38. Gadroen K, Dodd CN, Masclee GMC, de Ridder MAJ, Weibel D, Mina MJ, et al. Impact and longevity of measles-associated immune suppression: a matched cohort study using data from the THIN general practice database in the UK. BMJ open. 2018;8(11):e021465.
39. Bühl D, Staudacher O, Santibanez S, Rossi R, Girschick H, Stephan V, et al. Specifically Increased Rate of Infections in Children Post Measles in a High Resource Setting. Frontiers in Pediatrics. 2022;10.
40. Behrens L, Cherry JD, Heininger U, Swiss Measles Immune Amnesia Study G. The Susceptibility to Other Infectious Diseases Following Measles During a Three Year Observation Period in Switzerland. The Pediatric infectious disease journal. 2020;39(6):478-82.
41. Beckford AP, Kaschula RO, Stephen C. Factors associated with fatal cases of measles. A retrospective autopsy study. S Afr Med J. 1985;68(12):858-63.
42. Nelson AN, Lin WW, Shivakoti R, Putnam NE, Mangus L, Adams RJ, et al. Association of persistent wild-type measles virus RNA with long-term humoral immunity in rhesus macaques. JCI Insight. 2020;5(3).
43. Strebel PM, Orenstein WA. Measles. The New England journal of medicine. 2019;381(4):349-57.
44. Rota PA, Moss WJ, Takeda M, de Swart RL, Thompson KM, Goodson JL. Measles. Nature reviews Disease primers. 2016;2:16049.
45. Portnoy A, Jit M, Ferrari M, Hanson M, Brenzel L, Verguet S. Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and modelling analysis. The Lancet Global health. 2019;7(4):e472-e81.
46. Minta AA, Ferrari M, Antoni S, Lambert B, Sayi TS, Hsu CH, et al. Progress Toward Measles Elimination - Worldwide, 2000-2023. MMWR Morbidity and mortality weekly report. 2024;73(45):1036-42.
47. Gohil SK, Okubo S, Klish S, Dickey L, Huang SS, Zahn M. Healthcare Workers and Post-Elimination Era Measles: Lessons on Acquisition and Exposure Prevention. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016;62(2):166-72.
48. Hubiche T, Brazier C, Vabret A, Reynaud S, Roudiere L, Del Giudice P. Measles Transmission in a Fully Vaccinated Closed Cohort: Data From a Nosocomial Clustered Cases in a Teenage Psychiatric Unit. The Pediatric infectious disease journal. 2019;38(9):e230-e2.
49. Cherry JD, Zahn M. Clinical Characteristics of Measles in Previously Vaccinated and Unvaccinated Patients in California. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;67(9):1315-9.
50. Di Pietrantonj C, Rivetti A, Marchionne P, Debalini M, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database of Systematic Reviews. 2021;11(Art. No.: CD004407).
51. Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RCW, et al. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. Lancet (London, England). 2024;403(10441):2307-16.
52. Davidkin I, Jokinen S, Broman M, Leinikki P, Peltola H. Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: a 20-year follow-up. J Infect Dis. 2008;197(7):950-6.
53. Peltola H, Jokinen S, Paunio M, Hovi T, Davidkin I. Measles, mumps, and rubella in Finland: 25 years of a nationwide elimination programme. Lancet Infectious Diseases. 2008;8:796-803.
54. Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis. 2012;206(10):1542-8.

## FORTBILDUNG

55. Gidding HF, Quinn HE, Hueston L, Dwyer DE, McIntyre PB. Declining measles antibodies in the era of elimination: Australia's experience. *Vaccine*. 2018;36(4):507-13.
56. Bolotin S, Osman S, Hughes SL, Ariyarajah A, Tricco AC, Khan S, et al. In Elimination Settings, Measles Antibodies Wane Following Vaccination but Not Following Infection - A Systematic Review and Meta-Analysis. *J Infect Dis*. 2022.
57. Robert A, Suffel AM, Kucharski AJ. Long-term waning of vaccine-induced immunity to measles in England: a mathematical modelling study. *Lancet Public Health*. 2024;9(10):e766-e75.
58. Weisser K, Barth I, Keller-Stanislawska B. [Vaccine safety]. *Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz*. 2009;52(11):1053-64.
59. Peltola H, Heinonen OP. Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins. *Lancet (London, England)*. 1986;1(8487):939-42.
60. Strelbel P, Papania M, Fiebelkorn A, Halsey N. Measles Vaccines. In: Plotkin S, Orenstein W, editors. *Vaccines*. 6: Saunders Elsevier; 2013. p. 352-87.
61. Lievano FA, Galea SA, Thornton M, Wiedmann RT, Manoff SB, Tran TN, et al. Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experience. *Vaccine*. 2012;30 48:6918-26.
62. Mentzer D, Meyer H, Keller-Stanislawska B. [Safety and tolerability of monovalent measles and combined measles, mumps, rubella, and varicella vaccines]. *Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz*. 2013;56(9):1253-9.
63. Rieck T, Steffen A, Feig M, Rau C. Impfquoten in Deutschland - aktuelle Ergebnisse aus dem RKI-Impfquotenmonitoring. *Epidemiologisches Bulletin*. 2024;50:3-10.
64. Helfand RF, Kebede S, Gary HE, Jr., Beyene H, Bellini WJ. Timing of development of measles-specific immunoglobulin M and G after primary measles vaccination. *Clin Diagn Lab Immunol*. 1999;6(2):178-80.
65. Woods CR. False-Positive Results for Immunoglobulin M Serologic Results: Explanations and Examples. *J Pediatric Infect Dis Soc*. 2013;2(1):87-90.
66. Bolotin S, Lim G, Dang V, Crowcroft N, Gubbay J, Mazzulli T, et al. The utility of measles and rubella IgM serology in an elimination setting, Ontario, Canada, 2009-2014. *PLoS one*. 2017;12(8).
67. Kiehl W. *RKI-Fachwörterbuch Infektionsschutz und Infektionsepidemiologie*. Berlin: Robert Koch-Institute; 2015 2015.
68. Matysiak-Klose D, Mankertz A, Holzmann H. The Epidemiology and Diagnosis of Measles. *Deutsches Arzteblatt International*. 2024;121(26).